CO6890101A2 - Inhibidores de pde10 de pirimidina - Google Patents
Inhibidores de pde10 de pirimidinaInfo
- Publication number
- CO6890101A2 CO6890101A2 CO14042266A CO14042266A CO6890101A2 CO 6890101 A2 CO6890101 A2 CO 6890101A2 CO 14042266 A CO14042266 A CO 14042266A CO 14042266 A CO14042266 A CO 14042266A CO 6890101 A2 CO6890101 A2 CO 6890101A2
- Authority
- CO
- Colombia
- Prior art keywords
- pde10 inhibitors
- pyrimidine
- pyrimidine pde10
- inhibitors
- pde10
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527392P | 2011-08-25 | 2011-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6890101A2 true CO6890101A2 (es) | 2014-03-10 |
Family
ID=47746797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14042266A CO6890101A2 (es) | 2011-08-25 | 2014-02-27 | Inhibidores de pde10 de pirimidina |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9062059B2 (es) |
| EP (1) | EP2748151B1 (es) |
| JP (1) | JP5648147B2 (es) |
| KR (1) | KR101655635B1 (es) |
| CN (1) | CN103917528B (es) |
| AR (1) | AR087628A1 (es) |
| AU (1) | AU2012299080B2 (es) |
| BR (1) | BR112014004310B8 (es) |
| CA (1) | CA2845578C (es) |
| CL (1) | CL2014000450A1 (es) |
| CO (1) | CO6890101A2 (es) |
| CR (1) | CR20140085A (es) |
| CY (1) | CY1117622T1 (es) |
| DK (1) | DK2748151T3 (es) |
| DO (1) | DOP2014000039A (es) |
| EA (1) | EA023685B1 (es) |
| ES (1) | ES2572527T3 (es) |
| HK (1) | HK1193410A1 (es) |
| HR (1) | HRP20160635T1 (es) |
| HU (1) | HUE028451T2 (es) |
| IL (1) | IL230997A (es) |
| MA (1) | MA35508B1 (es) |
| ME (1) | ME02419B (es) |
| MX (1) | MX357241B (es) |
| MY (1) | MY157301A (es) |
| NI (1) | NI201400014A (es) |
| PE (1) | PE20141535A1 (es) |
| PL (1) | PL2748151T3 (es) |
| RS (1) | RS54788B1 (es) |
| SG (1) | SG2014013536A (es) |
| SI (1) | SI2748151T1 (es) |
| TN (1) | TN2014000070A1 (es) |
| TW (1) | TWI450895B (es) |
| UA (1) | UA109735C2 (es) |
| WO (1) | WO2013028590A1 (es) |
| ZA (1) | ZA201401272B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11999710B2 (en) | 2018-06-27 | 2024-06-04 | Hoffmann-La Roche Inc. | Radiolabeled cannabinoid receptor 2 ligand |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200001B2 (en) | 2011-10-06 | 2015-12-01 | Merck Sharp & Dohme Corp. | Triazolyl PDE10 inhibitors |
| EP2763672B1 (en) | 2011-10-06 | 2016-08-10 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
| EP2919781B1 (en) | 2012-11-15 | 2017-06-28 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as pde10 inhibitors |
| EP2919783B1 (en) | 2012-11-15 | 2018-01-31 | Merck Sharp & Dohme Corp. | Cyclopropyl imidazopyridine pde10 inhibitors |
| TW201422610A (zh) | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| US9273033B2 (en) | 2012-11-20 | 2016-03-01 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as PDE10 inhibitors |
| EP2922823B1 (en) * | 2012-11-20 | 2018-10-31 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| WO2014139150A1 (en) | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Substituted pyridizinone derivatives as pde10 inhibitors |
| EP3122745B1 (en) | 2014-03-24 | 2019-02-27 | Novartis AG | Monobactam organic compounds for the treatment of bacterial infections |
| WO2018095877A1 (en) * | 2016-11-28 | 2018-05-31 | Boehringer Ingelheim International Gmbh | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US11919894B2 (en) | 2021-03-17 | 2024-03-05 | Merck Sharp & Dohme Llc | Pro drugs of PDE10 compounds |
| WO2023184486A1 (en) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Process for preparing ( (1s, 2s) -2- (5-methylpyridin-2-yl) cyclopropyl) -methanol |
| CN115403527B (zh) * | 2022-07-20 | 2024-03-29 | 西安近代化学研究所 | 一种还原胺化法合成杀菌剂乙嘧酚的方法 |
| WO2024049721A1 (en) * | 2022-08-31 | 2024-03-07 | Merck Sharp & Dohme Llc | Sustained release delivery of a pde10 inhibitor |
| WO2024099135A1 (zh) * | 2022-11-11 | 2024-05-16 | 杭州中美华东制药有限公司 | 1,5-萘啶类cGAS抑制剂及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| JP4874983B2 (ja) | 2004-10-12 | 2012-02-15 | マックスリニアー，インコーポレイティド | デジタル発生中間周波を有する受信器アーキテクチャ |
| AU2005323794B2 (en) | 2005-01-07 | 2012-07-19 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as PDE10 inhibitors |
| GB0506883D0 (en) * | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
| CA2602372A1 (en) * | 2005-04-05 | 2006-10-12 | Astrazeneca Ab | Pyrimidine derivatives for use as anticancer agents |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| CA2650976A1 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| MX2011002399A (es) | 2008-09-04 | 2011-04-07 | Mitsubishi Tanabe Pharma Corp | Compuestos pirimidina tri-sustituida y su uso como inhibidores de fosfodiesterasa 10. |
| WO2010030027A1 (en) | 2008-09-10 | 2010-03-18 | Mitsubishi Tanabe Pharma Corporation | Aromatic nitrogen-containing 6-membered ring compounds and their use |
| TW201030001A (en) * | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| EP2376455B1 (en) * | 2008-12-17 | 2012-11-14 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| EP2621276B1 (en) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
| EP2621926B1 (en) * | 2010-09-30 | 2017-08-30 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
-
2012
- 2012-08-20 CA CA2845578A patent/CA2845578C/en active Active
- 2012-08-20 AU AU2012299080A patent/AU2012299080B2/en active Active
- 2012-08-20 DK DK12826375.3T patent/DK2748151T3/en active
- 2012-08-20 PL PL12826375.3T patent/PL2748151T3/pl unknown
- 2012-08-20 ES ES12826375.3T patent/ES2572527T3/es active Active
- 2012-08-20 JP JP2014527214A patent/JP5648147B2/ja active Active
- 2012-08-20 MX MX2014002178A patent/MX357241B/es active IP Right Grant
- 2012-08-20 TW TW101130166A patent/TWI450895B/zh active
- 2012-08-20 ME MEP-2016-101A patent/ME02419B/me unknown
- 2012-08-20 HU HUE12826375A patent/HUE028451T2/en unknown
- 2012-08-20 CN CN201280052330.4A patent/CN103917528B/zh active Active
- 2012-08-20 SI SI201230539A patent/SI2748151T1/sl unknown
- 2012-08-20 RS RS20160357A patent/RS54788B1/sr unknown
- 2012-08-20 MY MYPI2014000504A patent/MY157301A/en unknown
- 2012-08-20 SG SG2014013536A patent/SG2014013536A/en unknown
- 2012-08-20 US US14/239,603 patent/US9062059B2/en active Active
- 2012-08-20 EP EP12826375.3A patent/EP2748151B1/en active Active
- 2012-08-20 WO PCT/US2012/051522 patent/WO2013028590A1/en active Application Filing
- 2012-08-20 BR BR112014004310A patent/BR112014004310B8/pt active IP Right Grant
- 2012-08-20 EA EA201490492A patent/EA023685B1/ru not_active IP Right Cessation
- 2012-08-20 PE PE2014000255A patent/PE20141535A1/es active IP Right Grant
- 2012-08-20 KR KR1020147007427A patent/KR101655635B1/ko active IP Right Grant
- 2012-08-20 UA UAA201403008A patent/UA109735C2/ru unknown
- 2012-08-22 AR ARP120103086A patent/AR087628A1/es active IP Right Grant
-
2014
- 2014-02-16 IL IL230997A patent/IL230997A/en active IP Right Grant
- 2014-02-18 TN TNP2014000070A patent/TN2014000070A1/en unknown
- 2014-02-19 ZA ZA2014/01272A patent/ZA201401272B/en unknown
- 2014-02-24 CR CR20140085A patent/CR20140085A/es unknown
- 2014-02-24 NI NI201400014A patent/NI201400014A/es unknown
- 2014-02-25 CL CL2014000450A patent/CL2014000450A1/es unknown
- 2014-02-25 DO DO2014000039A patent/DOP2014000039A/es unknown
- 2014-02-27 CO CO14042266A patent/CO6890101A2/es unknown
- 2014-03-13 MA MA6829A patent/MA35508B1/fr unknown
- 2014-07-07 HK HK14106824.3A patent/HK1193410A1/zh unknown
-
2016
- 2016-06-08 HR HRP20160635TT patent/HRP20160635T1/hr unknown
- 2016-06-10 CY CY20161100512T patent/CY1117622T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11999710B2 (en) | 2018-06-27 | 2024-06-04 | Hoffmann-La Roche Inc. | Radiolabeled cannabinoid receptor 2 ligand |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6890101A2 (es) | Inhibidores de pde10 de pirimidina | |
| CO6970602A2 (es) | Inhibidores de quinasa | |
| SMT201500271B (it) | Inibitori di neprilisina | |
| CO6950481A2 (es) | Inhibidores de proteínas quinasas | |
| DK2710007T3 (da) | Kinasehæmmere | |
| DK3459942T3 (da) | DNA-PK-hæmmere | |
| CO6940421A2 (es) | Inhibidores de neprilisina | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| BR112014000653A2 (pt) | inibidores de tirosina quinase de bruton | |
| CO6781518A2 (es) | Inhibidores de neprilisina | |
| BR112013029620A2 (pt) | inibidores de tirosina quinase de bruton | |
| CR20140147A (es) | Inhibidores de aplicación viral | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| BR112013030095A2 (pt) | inibidores de atividade de lrrk2 cinase | |
| EP2785183A4 (en) | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | |
| BR112013024378A2 (pt) | novos derivados de pirimidina | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| IL232234A0 (en) | Inhibitors of aminopyrimidine kinase | |
| IL228928A0 (en) | Aminopyrimidine kinase inhibitors | |
| CO6990735A2 (es) | Inhibidores de pirazina cinasa | |
| CO6900148A2 (es) | Inhibidores de la enzima activadora de nedd8 | |
| BR112014001977A2 (pt) | inibidores seletivos de proteína quinase | |
| EP2621276A4 (en) | 2-ALKOXY-PYRIMIDINE-PDE10 INHIBITORS | |
| CO6920305A2 (es) | Heterociclilpiri(mi)dinilpirazol |